Your browser doesn't support javascript.
loading
Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation.
Polymeris, Alexandros A; Zietz, Annaelle; Schaub, Fabian; Meya, Louisa; Traenka, Christopher; Thilemann, Sebastian; Wagner, Benjamin; Hert, Lisa; Altersberger, Valerian L; Seiffge, David J; Lyrer, Flurina; Dittrich, Tolga; Piot, Ines; Kaufmann, Josefin; Barone, Lea; Dahlheim, Ludvig; Flammer, Sophie; Avramiotis, Nikolaos S; Peters, Nils; De Marchis, Gian Marco; Bonati, Leo H; Gensicke, Henrik; Engelter, Stefan T; Lyrer, Philippe A.
Afiliação
  • Polymeris AA; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Zietz A; Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.
  • Schaub F; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Meya L; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Traenka C; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Thilemann S; Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.
  • Wagner B; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Hert L; Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.
  • Altersberger VL; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Seiffge DJ; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Lyrer F; Department of Intensive Care Medicine, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Dittrich T; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Piot I; Department of Neurology, Inselspital, University Hospital and University of Bern, Bern, Switzerland.
  • Kaufmann J; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Barone L; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Dahlheim L; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Flammer S; Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.
  • Avramiotis NS; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Peters N; Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.
  • De Marchis GM; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
  • Bonati LH; Neurology and Neurorehabilitation, University Department of Geriatric Medicine Felix Platter, University of Basel, Basel, Switzerland.
  • Gensicke H; Medical Faculty, University of Basel, Basel, Switzerland.
  • Engelter ST; Medical Faculty, University of Basel, Basel, Switzerland.
  • Lyrer PA; Department of Neurology and Stroke Center, University Hospital Basel and University of Basel, Basel, Switzerland.
Eur Stroke J ; 7(3): 221-229, 2022 Sep.
Article em En | MEDLINE | ID: mdl-36082252
ABSTRACT

Background:

Data on the safety and effectiveness of once-daily (QD) versus twice-daily (BID) direct oral anticoagulants (DOAC) in comparison to vitamin K antagonists (VKA) and to one another in patients with atrial fibrillation (AF) and recent stroke are scarce. Patients and

methods:

Based on prospectively obtained data from the observational registry Novel-Oral-Anticoagulants-in-Ischemic-Stroke-Patients(NOACISP)-LONGTERM (NCT03826927) from Basel, Switzerland, we compared the occurrence of the primary outcome - the composite of recurrent ischemic stroke, major bleeding, and all-cause death - among consecutive AF patients treated with either VKA, QD DOAC, or BID DOAC following a recent stroke using Cox proportional hazards regression including adjustment for potential confounders.

Results:

We analyzed 956 patients (median age 80 years, 46% female), of whom 128 received VKA (13.4%), 264 QD DOAC (27.6%), and 564 BID DOAC (59%). Over a total follow-up of 1596 patient-years, both QD DOAC and BID DOAC showed a lower hazard for the composite outcome compared to VKA (adjusted HR [95% CI] 0.69 [0.48, 1.01] and 0.66 [0.47, 0.91], respectively). Upon direct comparison, the hazard for the composite outcome did not differ between patients treated with QD versus BID DOAC (adjusted HR [95% CI] 0.94 [0.70, 1.26]). Secondary analyses focusing on the individual components of the composite outcome revealed no clear differences in the risk-benefit profile of QD versus BID DOAC. Discussion and

conclusion:

The overall benefit of DOAC over VKA seems to apply to both QD and BID DOAC in AF patients with a recent stroke, without clear evidence that one DOAC dosing regimen is more advantageous than the other.
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article